June 13, 2017
Breast Cancer PDX Models
Patient-derived xenograft (PDX) models enhance predictability in oncology preclinical studies. Never established in vitro, PDX closely recapitulate original tumors, including histo- and molecular pathology, driver mutations, and oncogenic changes. This provides highly predictive models, correlating well with patient response to SoC, to inform on clinical ...
LEARN MORE
June 8, 2017
First Cancer Drug Approval Based on Biomarkers, not Tumor Location
For the first time in their history, the U.S. Food and Drug Administration has approved a cancer treatment based on a ...
LEARN MORE
June 6, 2017
PCSK9 Inhibitor Data in Diabetic Patients to be Highlighted at ADA 2017
Recent years have witnessed a change in cholesterol-lowering compounds - from your parents’ standard statin treatment ...
LEARN MORE
June 1, 2017
The Translatable Value of Spontaneously Obese Rhesus for New Insulin-Sensitizing Therapeutics
There's a critical need for novel treatment options to ameliorate insulin resistance, particularly in the face of the ...
LEARN MORE
May 30, 2017
How to Choose Patient-Derived Xenograft (PDX) Models
Starting to write this blog, I realized it could also be titled ‘What to Expect From a Good PDX Database’, as the ...
LEARN MORE
May 25, 2017
Preclinical Immuno-Oncology Models 101
The recent breakthrough of checkpoint inhibitors in oncology has demonstrated that the immune system is a critical ...
LEARN MORE
May 23, 2017
When to Use Conventional Cell Line Derived Xenograft Models
With the creation and increased use of “new” xenograft models (such as patient-derived xenografts, or PDX), we are often asked which is the right model to use for different in vivo studies, and when to use conventional “cell line derived” xenografts vs the patient-derived alternatives.
LEARN MORE
May 18, 2017
Can We Develop Translational Platforms that Model Multiple Aspects of Human Diabetes?
A significant challenge in the development of new anti-diabetic therapies is the lack of translational platforms that ...
LEARN MORE
May 12, 2017
When to add Patient-Derived Xenografts (PDX) to Preclinical Drug Development Programs
When are patient-derived xenografts most useful in your drug development pipeline?
LEARN MORE
May 9, 2017
The Beginners Guide to Patient-Derived Xenograft (PDX) Models
Here’s what you need to know about PDX and what to expect from them in your research.
LEARN MORE
May 5, 2017
Patient-Derived Xenograft Population Studies: A Better Preclinical Representation of the Clinical Drug Development Process
The most nerve wracking part of drug discovery is anxiously waiting for the first-in-man data. Is it safe? Will the drug help the patient? These are questions that keep us all up at night.
LEARN MORE
December 13, 2016
Targeting Cardio-Metabolic Disease Symposium
Highlights from the NASH symposium and panel discussion in Boston, MA (Sep 20-21, 2016) Amar Thyagarajan, PhD
LEARN MORE
October 6, 2016
Breast Cancer No Longer Scary as we Reveal Its Smarter Disguises
October is breast cancer awareness month and CrownBio has reviewed the latest breast cancer research to bring you the ...
LEARN MORE
September 27, 2016
All You Need to Know About Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty liver disease (NAFLD) is a complex condition where an excessive amount of fat accumulates in the ...
LEARN MORE
September 13, 2016
Obesity Linked To Self-Eating Beige Fat
Humans, like all mammals, have two types of fat with completely opposite functions: white, which stores energy and when ...
LEARN MORE